| abstract |
The invention discloses a product for predicting the sensitivity of melanoma patients to MAGE-A3 immunotherapy. The product includes a kit, and the kit includes a reagent for detecting the expression level of markers IL2RG, TMEM56, and/or ELFN1. The method and product provided by the invention predict the sensitivity of melanoma patients to MAGE-A3 immunotherapy, have the advantages of simple method, short time and high efficiency, and can provide guidance for the selection of individualized medicine and treatment plan. |